Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926387 | 0.93 | NAPEPLD (0.51) | NAPEPLDPIK3CAAKT1BRAFRAF1 | |
| SCHEMBL3105453 | 0.86 | NAPEPLD (0.50) | NAPEPLDPIK3CAAKT1BRAFRAF1 | |
| SCHEMBL13440188 | 0.86 | NAPEPLD (0.54) | NAPEPLDPIK3CABRAFRAF1 | |
| SCHEMBL11926315 | 0.85 | NAPEPLD (0.52) | NAPEPLDPIK3CABRAFRAF1MTOR | |
| SCHEMBL3106257 | 0.85 | RAF1 (0.52) | NAPEPLDPIK3CAAKT1BRAFRAF1 | |
| SCHEMBL11929794 | 0.85 | NAPEPLD (0.49) | NAPEPLDPIK3CAAKT1BRAFRAF1 | |
| SCHEMBL11926344 | 0.85 | NAPEPLD (0.49) | NAPEPLDPIK3CABRAFRAF1MAPT | |
| SCHEMBL11926345 | 0.85 | NAPEPLD (0.53) | NAPEPLDPIK3CAAKT1BRAFRAF1 | |
| SCHEMBL3108254 | 0.85 | NAPEPLD (0.48) | NAPEPLDPIK3CAAKT1BRAFRAF1 | |
| SCHEMBL3108261 | 0.85 | NAPEPLD (0.48) | NAPEPLDPIK3CAAKT1BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | NAPEPLD 1303/4885PIK3CA 2810/4885AKT1 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.